ITGAX and myasthenia gravis: Conversely, in rituximab-treated MuSK-MG subjects, these relationships were reversed, with T-bet (r = -0.93, p = 0.0077) and CD20 (r = -0.81, p = 0.050) expression in CD11c+ B cells negatively correlating with antibody levels.